These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31272141)

  • 1. Current status of pulmonary arterial hypertension in Korea.
    Jang AY; Chung WJ
    Korean J Intern Med; 2019 Jul; 34(4):696-707. PubMed ID: 31272141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
    Woodcock CC; Chan SY
    J Cardiovasc Pharmacol Ther; 2019 Jul; 24(4):334-354. PubMed ID: 30773044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.
    Chida-Nagai A; Sagawa K; Tsujioka T; Fujimoto T; Taniguchi K; Sasaki O; Izumi G; Yamazawa H; Masaki N; Manabe A; Takeda A
    Heart Vessels; 2020 Sep; 35(9):1307-1315. PubMed ID: 32285188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary arterial hypertension specific therapy: The old and the new.
    Zolty R
    Pharmacol Ther; 2020 Oct; 214():107576. PubMed ID: 32417272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary arterial hypertension in the elderly: Clinical perspectives.
    Rothbard N; Agrawal A; Fischer C; Talwar A; Sahni S
    Cardiol J; 2020; 27(2):184-193. PubMed ID: 30155860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.
    Narechania S; Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):131-141. PubMed ID: 31594400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.
    Dunmore BJ; Jones RJ; Toshner MR; Upton PD; Morrell NW
    Cardiovasc Res; 2021 Sep; 117(11):2309-2325. PubMed ID: 33399862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and risk factors for pulmonary arterial hypertension associated with primary Sjögren's syndrome: 15 new cases from a single center.
    Zhang N; Zhao Y; Wang H; Sun W; Chen M; Fan Q; Yang Z; Wei W
    Int J Rheum Dis; 2019 Sep; 22(9):1775-1781. PubMed ID: 31368254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical management of riociguat in patients with pulmonary arterial hypertension.
    Halank M; Tausche K; Grünig E; Ewert R; Preston IR
    Ther Adv Respir Dis; 2019; 13():1753466619868938. PubMed ID: 31438774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Importance of Baseline and Longitudinal Evaluation in the Follow-Up of Vasodilator Therapy in Pulmonary Arterial Hypertension.
    Wright L; Dwyer N; Wahi S; Marwick TH
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 1):2103-2111. PubMed ID: 30343091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
    Gerhardt F; Fiessler E; Olsson KM; Kayser MZ; Kovacs G; Gall H; Ghofrani HA; Badr Eslam R; Lang IM; Benjamin N; Grünig E; Halank M; Lange TJ; Ulrich S; Leuchte H; Held M; Klose H; Ewert R; Wilkens H; Pizarro C; Skowasch D; Wissmüller M; Hellmich M; Olschewski H; Hoeper MM; Rosenkranz S
    Circulation; 2024 May; 149(20):1549-1564. PubMed ID: 38606558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management.
    Correale M; Tricarico L; Grazioli D; Formica ES; Petrucci R; Persichella P; Di Biase M; Brunetti ND
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):725-738. PubMed ID: 31811420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update.
    Yang Y; Lin F; Xiao Z; Sun B; Wei Z; Liu B; Xue L; Xiong C
    Biomed Pharmacother; 2020 Sep; 129():110355. PubMed ID: 32559622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations for Inotrope and Vasopressor Use in Critically Ill Patients With Pulmonary Arterial Hypertension.
    Adie SK; Abdul-Aziz AA; Ketcham SW; Moles VM
    J Cardiovasc Pharmacol; 2022 Jan; 79(1):e11-e17. PubMed ID: 34654789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
    Leong ZP; Hikasa Y
    Vascul Pharmacol; 2019; 122-123():106599. PubMed ID: 31629919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary Artery Hypertension-Specific Therapy Improves Exercise Tolerance and Outcomes in Exercise-Induced Pulmonary Hypertension.
    Kusunose K; Yamada H; Nishio S; Hirata Y; Saijo Y; Torii Y; Yamada N; Ise T; Yamaguchi K; Fukuda D; Yagi S; Soeki T; Wakatsuki T; Sata M
    JACC Cardiovasc Imaging; 2019 Dec; 12(12):2576-2579. PubMed ID: 31422131
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of F-ASO and Targeted Medical Therapy in Patients With Secundum ASD and Severe PAH.
    Yan C; Pan X; Wan L; Li H; Li S; Song H; Liu Q; Zhang F; Liu Y; Jiang Y; Wang L; Fang W
    JACC Cardiovasc Interv; 2020 Sep; 13(17):2024-2034. PubMed ID: 32800498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 20. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.